GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects
Major depression affects about 10 percent of the adult population and is the second leading cause of disability in U.S. adults, according to the World Health Organization. Despite the availability of several different classes of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), 30 to 40 percent of adults are unresponsive to these medications. Moreover, SSRIs typically take weeks to work, which increases the risk for suicide.
Enter NMDA (N-methyl-D-aspartate) receptor modulators. In the 1970s, researchers linked the receptors to learning and memory. Biotech and pharmaceutical companies in the 1980s attempted to apply chemical blockers to these receptors as a means to prevent stroke. But blocking these receptors led to the opposite effect—–the rise of cardiovascular disease. Research in the field dampened until a glutamate receptor antagonist already approved for anesthesia, and known on the streets as “Special K”, ketamine, made headlines in the early 2000s. Human clinical studies demonstrated that ketamine can ward off major and bipolar depressive symptoms within 2 hours of administration and last for several days. Ketamine is fraught with serious side effects including excessive sleepiness, hallucinations, and substance abuse behavior.
“Ketamine lit the field back up,“ said Joseph Moskal, Ph.D., a molecular neurobiologist at Northwestern University and senior study author. “Our drug, GLYX-13, is very different. It does not block the receptor ion channel, which may account for why it doesn’t have the same side effects.”
Moskal’s journey with GLYX-13 came about from his earlier days as a Senior Staff Fellow in NIMH’s Intramural Research Program. While at NIMH, he created specific molecules, monoclonal antibodies, to use as new probes to understand pathways of learning and memory. Some of the antibodies he created were for NMDA receptors. When he moved to Northwestern University, Moskal converted the antibodies to small protein molecules. Comprised of only four amino acids, GLYX-13 is one of these molecules.
Previous electrophysiological and conditioning studies had suggested that GLYX-13, unlike ketamine, enhanced memory and learning in rats, particularly in the brain’s memory hub or hippocampus. GLYX-13 also produced analgesic effects. Using several rat behavioral and molecular experiments, Moskal’s research team tested four compounds: GLYX-13, an inactive, “scrambled” version of GLYX-13 that had its amino acids rearranged, ketamine, and the SSRI fluoxetine.
Results of the Study
GLYX-13 and ketamine produced rapid acting (1 hour) and long-lasting (24 hour) antidepressant-like effects in the rats. Fluoxetine, an SSRI that typically takes from 2–4 weeks to show efficacy in humans, did not produce a rapid antidepressant effect in this study. As expected, the scrambled GLYX-13 showed no antidepressant-like effects at all. The researchers observed none of the aforementioned side effects of ketamine in the GLYX-13–treated rats.
Protein studies indicated an increase in the hippocampus of the NMDA receptor NR2B and a receptor for the chemical messenger glutamate called AMPA. Electrophysiology studies in this brain region showed that GLYX-13 and ketamine promoted long-lasting signal transmission in neurons, known as long-term potentiation/synaptic plasticity. This phenomenon is essential in learning and memory. The researchers propose how GLYX-13 works: GLYX-13 triggers NR2B receptor activation that leads to intracellular calcium influx and the expression of AMPA, which then is responsible for increased communication between neurons.
These results are consistent with data from a recent Phase 2 clinical trial, in which a single administration of GLYX-13 produced statistically significant reductions in depression scores in patients who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of 7 days. After a single dose of GLYX-13, the drug’s antidepressant efficacy nearly doubled that seen with most conventional antidepressants after 4–6 weeks of dosing. GLYX-13 was well tolerated and it did not produce any of the schizophrenia-like effects associated with other NMDA receptor modulating agents.
The Latest Bing News on:
- A tendency to focus on the past plays a key role in increasing depressive symptoms among individuals with childhood traumaon July 1, 2021 at 4:23 pm
Findings from the Journal of Psychiatric Research point to a negative focus on the past as a fundamental aspect of depression. The study found that ...
- Aditum's 5th biotech will take another look at Taisho's failed depression drugon July 1, 2021 at 8:51 am
The investment firm Aditum is launching Ancora Bio with the exclusive rights to Taisho Pharmaceutical's depression drug candidate that last year fell short in a clinical trial. Ancora believes a fresh ...
- Issues and Symptoms Associated with Teenage Depressionon June 30, 2021 at 10:12 pm
One of your neighbors posted in Kids & Family . Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
- New postpartum depression treatment shows promising resultson June 30, 2021 at 9:21 pm
Scientists announced Wednesday that results from a clinical trial for zuranolone is showing promising results.
- Study: People With Depression May Not Adapt as Well to Stresson June 29, 2021 at 5:12 pm
A new study found that people with major depressive disorder may experience difficulty responding to stress. Different medications and therapies can help people with the condition better develop their ...
- Mild, Moderate or Severe Depression: How to Tell Which One You Haveon June 29, 2021 at 1:35 pm
"It's understandable that the social isolation that many people faced during the pandemic may have contributed to significant psychological stress and depression." Depression is classified as mild, ...
- Major Depressive Disorder Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2021-2026on June 29, 2021 at 10:13 am
Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and ...
- Surviving medical school with depressionon June 27, 2021 at 5:06 am
I was first diagnosed with major depressive disorder as a preteen after my teenage sister died. I attempted suicide three years later. This would be the first of several attempts and the first of ...
- Machine learning identifies new brain network signature of major depressionon June 26, 2021 at 12:27 pm
Machine learning is a method of data analysis that automates analytical model building. It is a branch of artificial intelligence based on the idea that ...
The Latest Google Headlines on:
The Latest Bing News on:
Fix the internet
- President Akufo-Addo is fixing the country with youth driven policies - Razak Opokuon July 2, 2021 at 7:52 pm
Mr Razak Kojo Opoku, a member of the New Patriotic Party has said, President Nana Addo Dankwa Akufo-Addo believes in Ghana and the ...
- Western Digital won’t fix a vulnerability found in older My Cloud OS3 storage deviceson July 2, 2021 at 2:32 pm
Owners of Western Digital network attached storage (NAS) devices may have yet another security headache on the horizon. Following the two flaws hackers exploited to wipe My Book Live devices remotely, ...
- False story about decuplets was a low point for journalism: how to fix the damageon July 2, 2021 at 6:28 am
Tighter controls are not the answer; the opportunity should be used to think differently about trust and journalism. It is critical to enable audiences to distinguish reliable, verified information.
- A medical moonshot would help fix inequality in American health careon July 2, 2021 at 5:50 am
COVID-19 has put the American health care system's deeply entrenched inequities into high relief. The social, economic and political structures that predated the pandemic's public health crisis and ...
- The internet’s economic model is broken – here’s how we can fix iton July 1, 2021 at 1:42 am
The underlying ad-tech economic model that currently powers the internet emerged by accident after the dot-com crash of 2000-2001. Until the crash, Google and other VC-funded dot- ...
- AC Feels Great, But It’s Terrible for the Planet. Here’s How to Fix Thaton June 30, 2021 at 1:07 pm
We came close to destroying the planet with air conditioning before. We're heading that direction again. We need to rethink how we cool.
- Women are being squeezed by the pandemic. Here's how to fix iton June 30, 2021 at 2:08 am
To those attending the historic Paris gender forum we have a simple message: close the gender gap to build a better post-pandemic future ...
- Technology Law & Policy Clinic Students Represent iFixit To File Comment with Copyright Office and Protect the Public’s Right To Repairon June 29, 2021 at 2:05 pm
Technology Law & Policy Clinic Students Represent iFixit To File Comment with Copyright Office and Protect the Public’s Right To Repair. This post is part of a series exploring ...
- What’s next for the Afghan air force? Learning to fix aircraft via video conferencingon June 29, 2021 at 11:31 am
Afghans who maintain the country’s military aircraft have been learning to fix damaged aircraft over the past two months via videoconferences with U.S.-funded contractors just a few rooms away. It’s ...
- The major health care and cybersecurity risk of 'Right-to-Repair' lawson June 29, 2021 at 11:00 am
Just like other devices we rely on, medical devices can improve our quality of life - so long as they are maintained to work properly. When they are not - or not maintained or serviced in line with ...